Primary progressive multiple sclerosis

Brain

Volumn 120, Issue 6, 1997, Pages 1085-1096

  Thompson, A J ^a,g   Polman, C H ^b   Miller, D H ^a   McDonald, W I ^a   Brochet, B ^c   Filippi, M ^d   Montalban, X ^e   De Sa J ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HÔPITAL PELLEGRIN   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g National Hospital   (United Kingdom)

Author keywords

Diagnosis; Multiple sclerosis; Primary progressive

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; GENETIC ASSOCIATION; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; NEUROLOGY; NEUROPHYSIOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SPINAL CORD DISEASE;

EID: 0030911461     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.6.1085     Document Type: Review

References (96)

1. Acarín N, Río J, Fernández AL, Tintoré M, Durán I, Galán I, et al. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99-103.
2. Allen IV, Glover G, Anderson R. Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol (Berl) 1981; suppl VII: 176-8.
3. Barnes D, Munro PMG, Youl BD, Prineas JW, McDonald WI. The longstanding MS lesion: a quantitative MRI and electron microscopic study. Brain 1991; 114: 1271-80.
4. Cazzato G, Mesiano T, Antonello R, Monti F, Carraro N, Torre P, et al. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 1995; 35: 193-8.
5. Chalon MP, Sindic CJM, Laterre EC. Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. Acta Neurol Scand 1993: 87: 77-82.
6. Comi G, Filippi M, Martinelli V, Campi A, Rodegher M, Alberoni M, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995; 132: 222-7.
7. Compston DAS, Kellar Wood H, Robertson N, Sawcer S, Wood NW. Genes and susceptibility to multiple sclerosis. [Review]. Acta Neurol Scand 1995; Suppl 161: 43-51.
8. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
9. Cowan J, Ormerod IE, Rudge P. Hemiparetic multiple sclerosis. J Neurol Neurosurg Psychiatry 1990; 53: 675-80.
10. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Miller DH, et al. A proton spectroscopy study of disability in multiple sclerosis [abstract]. J Neurol 1996; 243 Suppl 2: S33.
11. de Sá J, Magalhàes MA. Multimodal evoked potentials in primary progressive and relapsing/remitting MS forms. ECTRIMS 9th Congress Book of Abstracts 1993; 90.
12. Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Searano F, et al. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging [published erratum appears in Radiology 1992; 183: 878]. Radiology 1992; 182: 483-91.
13. Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, et al. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med 1984; 311: 948-53
14. Filippi M, Martinelli V, Locatelli T, Medaglini S, Poggi A, Visciani A, et al. Acute-and insidious-onset myelopathy of undetermined aetiology: contribution of paraclinical tests to the diagnosis of multiple sclerosis. J Neurol 1990; 237: 171-6.
15. Filippi M, Campi A, Martinelli V, Rodegher M, Scotti G, Canal N, et al. A brain MRI study of different types of chronic-progressive multiple sclerosis. Acta Neurol Scand 1995a; 91: 178-82.
16. Filippi M, Campi A, Martinelli V, Colombo B, Yousry T, Canal N, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995b; 59: 540-4.
17. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995c; 45: 478-82.
18. Francis DA, Batchelor JR, McDonald WI, Hing SN, Dodi IA, Fielder AH, et al. Multiple sclerosis in north-east Scotland: an association with HLA DQw1. Brain 1987; 110: 181-96.
19. Frequin STFM, Lamers KJB, Barkhof F, Borm GF, Hommes OR. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 1994; 90: 105-10.
20. Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36: 62-7.
21. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996; 60:20-6.
22. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis: implications for clinical trials. Arch Neurol 1989; 46: 1107-12.
23. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
24. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
25. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
26. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J et al. Low-dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis [see comments]. Ann Neurol 1995; 37: 30-40. Comment in: Ann Neurol 1995; 37: 5-6, Comment in: Ann Neurol 1995; 38: 832-3, Comment in: Ann Neurol 1996; 39: 684.
27. Hillert J, Grönning M, Nyland H, Link H, Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55:887-90.
28. Hohlfeld R. Biotechnological products for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997. In press.
29. Hughes RAC, Sharrack B. More immunotherapy for multiple sclerosis [editorial]. J Neurol Neurosurg Psychiatry 1996; 61: 239-41.
30. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972; 1: 1240-1.
31. Kappos L, Städt D, Rohrbach E, Keil W. Gadolinium-DTPA-enhanced magnetic resonance imaging in the evaluation of different disease courses and disease activity in MS [abstract]. Neurology 1988; 38 Suppl 1: 255.
32. Kidd DK, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacManus DG et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993; 43: 2632-7.
33. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 15-9.
34. Kidd D, Barker GJ, Tofts PS, Gass A, Thompson AJ, McDonald WI, et al. The transverse magnetic decay characteristics of long standing lesions and normal appearing white matter in MS. J Neurol 1997; 244: 125-30.
35. Kurtzke JF. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology 1965; 15: 654-61.
36. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52,
37. Larsen JP, Kvaale G, Riise T, Nyland H, Aarli JA. Multiple sclerosis-more than one disease? Acta Neurol Scand 1985; 72: 145-50.
38. Leibowitz U, Alter M, Halpern L. Clinical studies of multiple sclerosis in Israel. III. Clinical course and prognosis related to age at onset. Neurology 1964; 14: 926-32.
39. Losseff NA, Kingsley DPE, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996a; 1:218-22.
40. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996b; 119: 701-8.
41. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
42. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 1996; 6: 259-74.
43. Lycklama à Nijeholt GJ, Barkhof F, Scheltens P, Castelijns JA, Adèr H, van Waesberghe JH et al. Diffuse abnormality on magnetic resonance imaging of the spinal cord in multiple sclerosis: relation with clinical subtype and disability. AJNR Am J Neuro Radiol 1997. In press.
44. McDonald WI. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. [Review]. J Neuropathol Exp Neurol 1994; 53: 338-43.
45. Madigand M, Oger JJ-F, Fauchert R, Sabouraud O, Genetet B. HLA profiles in multiple sclerosis suggest two forms of disease and the existence of protective haplotypes. J Neurol Sci 1982; 53: 519-29.
46. Magalhàes A, de Sá J. CSF profiles in primary progressive and relapsing/remitting forms of multiple sclerosis. ECTRIMS 9th Congress Book of Abstracts 1993; 74.
47. Marshall J. Spastic paraplegia of middle age: a clinicopathological study. Lancet 1955; 1: 643-6.
48. Marzo ME, Tintore M, Molina C, Comabella M, Rio J, Rovira A, et al. Multiple sclerosis and Sjogren's syndrome. Eur Neurol 1997. In press.
49. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotrophic virus type-1-associated myelopathy. J Neuroimmunol 1995; 59: 35-40.
50. Matthews WB. Clinical aspects: course and prognosis. In: Matthews WB, Compston A, Allen IV, Martyn CN, editors. McAlpine's multiple sclerosis. 2nd Ed. Edinburgh: Churchill Livingstone, 1991: 147.
51. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis (PPMS) in Northern Ireland [abstract]. J Neurol 1996; 243 Suppl 2: S2-S5.
52. Midgard R, Riise T, Nyland H. Epidemiologic trends in multiple sclerosis in More and Romsdal, Norway: a prevalence/incidence study in a stable population. Neurology 1991; 41: 887-92.
53. Miller DH, McDonald WI, Blumhardt LD, du Boulay GH, Halliday AM, Johnson G, et al. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol 1987; 22: 714-23.
54. Miller DH, Newton MR, van der Poel JC, du Boulay EPGH, Halliday AM, Kendall BE, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1988; 38: 175-9.
55. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-6.
56. Mills CK, Spiller WG. A case of progressively developing hemiplegia, later becoming triplegia, resulting from primary degeneration of the pyramidal tracts. J Nerv Ment Dis 1903; 7: 1-13.
57. Minderhoud JM, van der Hoeven JH, Prange AJA. Course and prognosis of chronic progressive multiple sclerosis. Acta Neurol Scand 1988; 78: 10-5
58. Miska RM, Pojunas KW, McQuillen MP. Cranial magnetic resonance imaging in the evaluation of myelopathy of undetermined etiology. Neurology 1987; 37: 840-3.
59. Morrissey SP, Borruat FX, Miller DH, Moseley IF, Sweeney MG, Govan GG, et al. Bilateral simultaneous optic neuropathy in adults: clinical, imaging, serological, and genetic studies, J Neurol Neurosurg Psychiatry 1995; 58: 70-4.
60. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Moller E, et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 1989; 86: 7113-7.
61. Ormerod IEC, McDonald WI. Multiple sclerosis presenting with progressive visual failure. J Neurol, Neurosurg Psychiatry 1984; 47: 943-6.
62. Paty DW, Blume WT, Brown WF, Jaatoul N, Kertesz A, McInnis W. Chronic progressive myelopathy: investigation with CSF electrophoresis, evoked potentials, and CT scan. Ann Neurol 1979; 6: 419-24.
63. Peter JB, Boctor FN, Tourtellotte WW. Serum and CSF levels of IL-2, slL-2R, TNF-α, and 1L-lβ in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 1991; 41: 121-3.
64. Pirttilä T, Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol Scand 1995; 92: 468-71.
65. Poser CM, Paty PW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
66. Poser S, Poser W, Schlaf G, Firnhaber W, Laver K, Wolter M, et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986; 74: 387-92.
67. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
68. Robertson NP, Clayton D, Fraser M, Deans J, Compston DAS. Clinical concordance in sibling pairs with multiple sclerosis. Neurology 1996; 47: 347-52.
69. Robinson K, Rudge P, Small DG, Storey CE. A survey of the pattern reversal visual evoked response (PRVER) in 1428 consecutive patients referred to a clinical neurophysiology department. J Neurol Sci 1984; 64: 225-43.
70. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system [see comments]. Ann Neurol 1990; 27: 12-17. Comment in: Ann Neurol 1992; 32: 834-5.
71. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system [see comments]. Ann Neurol 1990; 27: 12-17. Comment in: Ann Neurol 1992; 32: 834-5.
72. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-34.
73. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis [see comments]. New Engl J Med 1991; 325: 467-72. Comment in: New Engl J Med 1992; 326: 272-3.
74. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis [see comments]. New Engl J Med 1991; 325: 467-72. Comment in: New Engl J Med 1992; 326: 272-3.
75. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, et al. Enhancing lesion detection in multiple sclerosis: effects of gadolinium dose, magnetisation transfer and delayed scanning [abstract]. J Neurol 1996; 243 Suppl 2: S69.
76. Stevenson VL, Thompson AJ, Polman C, Filippi M, Montalban X, Brochet B, et al. Study designs of the MAGNIMS clinical and MRI study of patients with primary progressive multiple sclerosis. Eur J Neurol 1996; 3 Suppl 4: 11.
77. Thompson AJ, Noseworthy JH. New treatments for multiple sclerosis: a clinical perspective. Curr Opin Neurol 1996; 9: 187-98.
78. Thompson AJ, Hutchinson M, Martin EA, Mansfield M, Whelan A, Feighery C. Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course. J Neurol Neurosurg Psychiatry 1985; 48: 989-94.
79. Thompson AJ, Hutchinson M, Brazil J, Feighery C, Martin EA. A clinical and laboratory study of benign multiple sclerosis. Q J Med 1986; 58: 69-80.
80. Thompson AJ, Kermode AJ, MacManus DG, Kingsley DPE, Kendall BE, Moseley IF, et al. Pathogenesis of progressive multiple sclerosis [letter]. Lancet 1989; 1: 1322-3.
81. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study [see comments]. BMJ 1990; 300: 631-34. Comment in: BMJ 1990; 300: 1272.
82. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study [see comments]. BMJ 1990; 300: 631-34. Comment in: BMJ 1990; 300: 1272.
83. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29:53-62.
84. Thorpe JW, Kendall BE, MacManus DG, McDonald WI, Miller DH. Dynamic gadolinium-enhanced MRI in the detection of spinal arteriovenous malformations. Neuroradiology 1994; 36: 522-9.
85. Thorpe JW, Kidd D, Moseley IF, Thompson AJ, MacManus DG, Compston DAS, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996; 119: 709-14.
86. Tourtellotte WW, Baumhefner RW, Syndulko K, Shapshak P, Osborne M, Rubinshtein G, et al. The long march of the cerebrospinal fluid profile indicative of clinical definite multiple sclerosis; and still marching. J Neuroimmunol 1988; 20: 217-27.
87. Van Lambalgen R, Sanders EACM, D' Amaro J. Sex distribution,age of onset and HLA profiles in two types of multiple sclerosis. J Neurol Sci 1986; 76:13-21.
88. Vleugels L, Pfennings LEMA, Pouwer F, Cohen L, Ketelaer P, Polman CH, et al. Psychological functioning in primary progressive versus secondary progressive multiple scelrosis. Br J Med Psychol 1977. In press.
89. Warren KG, Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci 1994; 121: 468-73.
90. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis [see comments]. Neurology 1993; 43: 910-18. Comment in: Neurology 1994; 44: 579-81.
91. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis [see comments]. Neurology 1993; 43: 910-18. Comment in: Neurology 1994; 44: 579-81.
92. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 1, Clinical course and disability. Brain 1989; 112: 133-46.
93. Weinshenker BG, Gilbert JJ, Ebers GC. Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. J Neurol Neurosurg Psychiatry 1990; 53: 146-9
94. Weinshenker BG, Santrach P, Schaid D, Rodriguez M. Association between class II major histocompatibility complex polymorphisms and the course of multiple sclerosis [abstract]. Neurology 1995; 45 Suppl 4: A384.
95. Yamamoto T, Llena J, Kim E S, Hirano A. Chronic encephalomyelitis presenting as chronic progressive myelophathy. J Neurol Neurosurg Psychiatry 1984; 47: 1192-6.
96. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991; 114: 2437-50.